<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">32220</article-id><article-id pub-id-type="doi">10.17116/terarkh201789284-90</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice</article-title><trans-title-group xml:lang="ru"><trans-title>Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Andreev</surname><given-names>D N</given-names></name><name xml:lang="ru"><surname>Андреев</surname><given-names>Д Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dicheva</surname><given-names>D T</given-names></name><name xml:lang="ru"><surname>Дичева</surname><given-names>Д Т</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Maev</surname><given-names>I V</given-names></name><name xml:lang="ru"><surname>Маев</surname><given-names>И В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Московский государственный медико-стоматологический университет им. А.И. Евдокимова Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2017</year></pub-date><volume>89</volume><issue>2</issue><issue-title xml:lang="en">VOL 89, NO2 ()</issue-title><issue-title xml:lang="ru">ТОМ 89, №2 (2017)</issue-title><fpage>84</fpage><lpage>90</lpage><history><date date-type="received" iso-8601-date="2020-04-10"><day>10</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/32220">https://ter-arkhiv.ru/0040-3660/article/view/32220</self-uri><abstract xml:lang="en"><p>A steady decline in the effectiveness of standard eradication therapy (ET) regimens for Helicobacter pylori infection necessitates a search for ways of their optimization, by enhancing the efficiency of treatment protocols and by improving their safety and tolerability. The review systematizes the data available in the literature on main accessible methods for optimizing ET regimens. Among the optimization methods that can considerably enhance the efficiency of ET regimens, one may identify their addition of a bismuth agent (by 10—20%), the use of rebamipide (by 11.9%), adjuvant therapy with probiotics (by 8.1—13%), or double-dose proton pump inhibitors (by 8%). Only adjuvant therapy with probiotics results in a significant decrease in the incidence of side effects from ET. In posteradication period, rebamipide should be used to potentiate gastric mucosal repair and to regress inflammatory processes.</p></abstract><trans-abstract xml:lang="ru"><p>Аннотация Неуклонное снижение эффективности стандартных схем эрадикационной терапии (ЭТ) инфекции Helicobacter pylori делает неизбежным поиск путей их оптимизации за счет повышения эффективности и улучшения безопасности и переносимости протоколов лечения. В обзоре систематизированы данные литературы об основных доступных методах оптимизации схем ЭТ. Среди методов оптимизации, позволяющих значительно повысить эффективность ЭТ, можно выделить добавление в них препарата висмута (на 10—20%), использование ребамипида (на 11,9%), использование адъювантной терапии с применением пробиотиков (на 8,1—13%) и двойных доз ингибиторов протонного насоса (на 8%). Достоверное снижение частоты развития побочных явлений на фоне ЭТ достигается только с использованием адъювантной терапии с применением пробиотиков. В постэрадикационный период целесообразно использование ребамипида для потенцирования репарации слизистой оболочки желудка и регрессии воспалительных процессов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Helicobacter pylori</kwd><kwd>eradication therapy</kwd><kwd>optimization</kwd><kwd>compliance</kwd><kwd>proton pump inhibitors</kwd><kwd>pariet (brand name</kwd><kwd>rabeprazole)</kwd><kwd>probiotics</kwd><kwd>bismuth tripotassium dicitrate</kwd><kwd>rebamipide</kwd><kwd>Helicobacter pylori</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>эрадикационная терапия</kwd><kwd>оптимизация</kwd><kwd>приверженность</kwd><kwd>ингибиторы протонного насоса</kwd><kwd>париет (оригинальный рабепразол)</kwd><kwd>пробиотики</kwd><kwd>висмута трикалия дицитрат</kwd><kwd>ребамипид</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Маев И.В., Самсонов А.А., Андреев Д.Н. Инфекция Helicobacter pylori. М.: ГЭОТАР-Медиа; 2016.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Маев И.В., Самсонов А.А., Андреев Д.Н., Гречушников В.Б., Коровина Т.И. Клиническое значение инфекции Helicobacter pylori. Клиническаямедицина. 2013;91(8):4-12.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015; 64(9):1353-1367. doi:10.1136/gutjnl-2015-309252</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol. 2014; 11(10):628-638. doi:10.1038/nrgastro.2014.99</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Peek RM Jr, Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol. 2006;208(2):233-248. doi:10.1002/path.1868</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19(3):449-490. doi:10.1128/CMR.00054-05</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Маев И.В., Андреев Д.Н., Самсонов А.А., Дичева Д.Т., Парцваниа-Виноградова Е.В. Эволюция представлений о дефиниции, классификации, диагностике и лечении гастрита, ассоциированного с инфекцией Helicobacter pylori (по материалам Киотского консенсуса, 2015). Фарматека. 2016;6:24-33.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2016. pii: gutjnl-2016-312288. doi:10.1136/gutjnl-2016-312288</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016;14(6):577-585. doi:10.1080/14787210.2016.1178065</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Safavi M, Sabourian R, Foroumadi A. Treatment of Helicobacter pylori infection: Current and future insights. World J Clin Cases. 2016;4(1):5-19. doi:10.12998/wjcc.v4.i1.5</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772-781. doi:10.1136/gut.2006.101634</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Тер. архив. 2014;3:94-99.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Maev IV, Andreev DN, Kucheryavyi YuA, Dicheva DT. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J. 2014;30:134-140. doi:10.5829/idosi.wasj.2014.30.mett.61</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015;19(12):1637-1650. doi:10.1517/14728222.2015.1073261</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Актуальные возможности оптимизации антихеликобактерной терапии. Лечащийврач. 2014;4:73-79.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Sabaté E, ed. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>O’Connor JP, Taneike I, O’Morain C. Improving compliance with Helicobacter pylori eradication therapy: when and how? Therap Adv Gastroenterol. 2009;2(5):273-279. doi:10.1177/1756283X09337342</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Wermeille J, Cunningham M, Dederding JP, Girard L, Baumann R, Zelger G, Buri P, Metry JM, Sitavanc R, Gallaz L, Merki H, Godin N.Failure of Helicobacter pylori eradication: is poor compliance the main cause? Gastroenterol Clin Biol. 2002;26(3):216-219.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Tschabitscher D, Platzer P, Baumgärtel C, Müllner M. Generic drugs: quality, efficacy, safety and interchangeability. WienKlinWochenschr. 2008;120(3-4):63-69. doi:10.1007/s00508-008-0927-3</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Передерий В.Г., Чернявский В.В. Медико-экономическая эффективность стандартных схем эрадикации H. pylori с включением оригинального и генерического рабепразола. Здоров’яУкраїни. 2006;21/1:28-29.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Cammarota S, Bruzzese D, Sarnelli G, Citarella A, Menditto E, Riegler S, Savino IG, Vozzella L, Piccinocchi G, Napoli L, Arpino G, Cuomo R. Proton pump inhibitors prescribing following the introduction of generic drugs. Eur J Clin Invest. 2012;42(10):1068-1078. doi:10.1111/j.1365-2362.2012.02696.x</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Tepes B, O’Connor A, Gisbert J, O’Morain C. Treatment of Helicobacter pylori infection 2012. Helicobacter. 2012;17(Suppl.1):36-42. doi:10.1111/j.1523-5378.2012.00981.x</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Vallve M, Vergara M, Gisbert J P, Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther. 2002; 16(6):1149-1156. doi:10.1046/j.1365-2036.2002.01270.x</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008;28(7):868-877. doi:10.1111/j.1365-2036.2008.03807.x</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36(5):414-425. doi:10.1111/j.1365-2036.2012.05211.x</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Chaudhry AS, Kochhar R, Kohli KK. Genetic polymorphism of CYP2C19 &amp; therapeutic response to proton pump inhibitors. Indian J Med Res. 2008;127(6):521-530.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC, Kuo FC. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 2014;20 (43):16029-16036. doi:10.3748/wjg.v20.i43.16029</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Zvyaga T, Chang SY, Chen C, Yang Z, Vuppugalla R, Hurley J, Thorndike D, Wagner A, Chimalakonda A, Rodrigues AD. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos. 2012;40(9):1698-1711. doi:10.1124/dmd.112.045575</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Skoczylas T, Sarosiek I, Sostarich S, McElhinney C, Durham S, Sarosiek J. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci. 2003;48(2):322-328.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Jaworski T, Sarosiek I, Sostarich S, Roeser K, Connor M, Brotze S, Wallner G, Sarosiek J. Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig Dis Sci. 2005;50(2):357-365.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Tsutsui N, Taneike I, Ohara T, Goshi S, Kojio S, Iwakura N, Matsumaru H, Wakisaka-Saito N, Zhang HM, Yamamoto T. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori. Antimicrob Agents Chemother. 2000;44(11):3069-3073.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Ohara T, Goshi S, Taneike I, Tamura Y, Zhang HM, Yamamoto T. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori. Helicobacter. 2001;6(2):125-129.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Zhang Z, Liu ZQ, Zheng PY, Tang FA, Yang PC. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. WorldJGastroenterol. 2010;16(10):1279-1284.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Кучерявый Ю.А., Андреев Д.Н. Перспективы лечения больных с кислотозависимыми заболеваниями. Клин. перспективы гастроэнтерол., гепатол. 2014;2:15-24.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Akazawa Y, Fukuda D, Fukuda Y. Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence. Therap Adv Gastroenterol. 2016;9(6):845-852. doi:10.1177/1756283X16668093</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439-1446. doi:10.1136/gutjnl-2015-311304</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. Am J Gastroenterol. 2016;111(7):949-956. doi:10.1038/ajg.2016.182</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Ge R, Chen Z, Zhou Q. The actions of bismuth in the treatment of Helicobacter pylori infections: an update. Metallomics. 2012;4(3):239-243. doi:10.1039/c2mt00180b</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Alkim H, Koksal AR, Boga S, Sen I, Alkim C. Role of Bismuth in the Eradication of Helicobacter pylori. Am J Ther. 2016 Jan 21.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Bland MV, Ismail S, Heinemann JA, Keenan JI. The action of bismuth against Helicobacter pylori mimics but is not caused by intracellular iron deprivation. Antimicrob Agents Chemother. 2004;48(6):1983-1988. doi:10.1128/AAC.48.6.1983-1988.2004</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Stratton CW, Warner RR, Coudron PE, Lilly NA. Bismuth-mediated disruption of the glycocalyx-cell wall of Helicobacter pylori: ultrastructural evidence for a mechanism of action for bismuth salts. J Antimicrob Chemother. 1999;43(5):659-666.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Клинико-молекулярные аспекты резистентности Helicobacter pylori к антибактериальным препаратам. Мед. совет. 2013;10:11-15.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Williamson R, Pipkin GA. Does bismuth prevent antimicrobial resistance of Helicobacter pylori? Helicobacter pylori. Basic Mechanisms to Clinical Cure 1998. Ed. by RH Hunt, GNJ Tytgat. Dordrecht; Boston; London: Kluwer Acad. Publ., 1998:416-425.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, Lu H. High efficacy of 14-ay triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010;15(3):233-238. doi:10.1111/j.1523-5378.2010.00758.x</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Yoon JH, Baik GH, Kim YS, Suk KT, Shin WG, Kim KH, Kim KO, Park CH, Baik IH, Jang HJ, Kim JB, Kae SH, Kim DJ, Kim HY. Comparison of the Eradication Rate between 1-nd 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication. Gut Liver. 2012;6(4):434-439. doi:10.5009/gnl.2012.6.4.434</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Liao J, Zheng Q, Liang X, Zhang W, Sun Q, Liu W, Xiao S, Graham DY, Lu H. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013;18:373-377. doi:10.1111/hel.12052</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Cao Z, Chen Q, Zhang W, Liang X, Liao J, Liu W, Xiao S, Lu H. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Scand J Gastroenterol. 2015;50(10): 1185-1190. doi:10.3109/00365521.2015.1037345</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65(5):870-878. doi:10.1136/gutjnl-2015-311019</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Маев И.В., Самсонов А.А., Коровина Т.И., Гречушников В.Б., Андреев Н.Г. Висмута трикалия дицитрат повышает эффективность антихеликобактерной терапии первой линии. Эксперимент. и клин. гастроэнтерол. 2012;8:92-97.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Бордин Д.С., Машарова А.А., Хомерики С.Г. Хронический гастрит: современный взгляд на старую проблему. Эксперимент. иклин. гастроэнтерол. 2012;5:99-106.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Iinuma S, Naito Y, Yoshikawa T, Takahashi S, Takemura T, Yoshida N, Kondo M. In vitro studies indicating antioxidative properties of rebamipide. Dig Dis Sci. 1998;43(9 Suppl):35S-39S.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Yoshida N, Yoshikawa T, Iinuma S, Arai M, Takenaka S, Sakamoto K, Miyajima T, Nakamura Y, Yagi N, Naito Y, Mukai F, Kondo M. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci. 1996;41(6):1139-1144.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261-270. doi:10.1586/egh.10.25</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Haruma K, Ito M. Review article: clinical significance of mucosal-protective agents: acid, inflammation, carcinogenesis and rebamipide. Aliment Pharmacol Ther. 2003;18(Suppl.1):153-159. doi:10.1046/j.1365-2036.18.s1.17.x</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Haruma K, Ito M, Kido S, Manabe N, Kitadai Y, Sumii M, Tanaka S, Yoshihara M, Chayama K. Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci. 2002;47(4):862-867.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Kamada T, Sato M, Tokutomi T, Watanabe T, Murao T, Matsumoto H, Manabe N, Ito M, Tanaka S, Inoue K, Shiotani A, Akiyama T, Hata J, Haruma K. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int. 2015; 2015:865146. doi:10.1155/2015/865146</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Nishizawa T, Nishizawa Y, Yahagi N, Kanai T, Takahashi M, Suzuki H. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29(Suppl.4):20-24. doi:10.1111/jgh.12769</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Terano A, Arakawa T, Sugiyama T, Suzuki H, Joh T, Yoshikawa T, Higuchi K, Haruma K, Murakami K, Kobayashi K; Rebamipide Clinical Study Group. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol. 2007;42(8):690-693. doi:10.1007/s00535-007-2076-2</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Marcus EA, Sachs G, Scott DR. Eradication of Helicobacter pylori Infection. Curr Gastroenterol Rep. 2016;18(7):33. doi:10.1007/s11894-016-0509-x</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Pinchuk IV, Bressollier P, Verneuil B, Fenet B, Sorokulova IB, Mégraud F, Urdaci MC. In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. Antimicrob Agents Chemother. 2001;45(11):3156-3161. doi:10.1128/AAC.45.11.3156-3161.2001</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Lesbros-Pantoflickova D., Corthésy-Theulaz I., Blum A. L. Helicobacter pylori and probiotics. J Nutr. 2007;137(3,Suppl.2): 812S-818S.</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Zhou C, Ma FZ, Deng XJ, Yuan H, Ma HS. Lactobacilli inhibit interleukin-8 production induced by Helicobacter pylori lipopolysaccharide-activated Toll-like receptor 4. World J Gastroenterol. 2008;14(32):5090-5095. doi:10.3748/wjg.14.5090</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009;14(5):97-107. doi:10.1111/j.1523-5378.2009.00716.x</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32(9):1069-1079. doi:10.1111/j.1365-2036.2010.04457.x</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Wang ZH, Gao QY, Fang JY. Meta-Analysis of the Efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47(1):25-32. doi:10.1097/MCG.0b013e318266f6cf</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Lv Z, Wang B, Zhou X, Wang F, Xie Y, Zheng H, Lv N. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis. Exp Ther Med. 2015;9(3):707-716. doi:10.3892/etm.2015.2174</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Kamdeu Fansi AA, Guertin JR, LeLorier J. Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea. J Med Econ. 2012;15(1):53-60. doi:10.3111/13696998.2011.629015</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Самсонов А.А., Гречушников В.Б., Андреев Д.Н., Юренев Г.Л., Лежнева Ю.А., Маев И.В. Оценка фармакоэкономических показателей лечения пациентов с заболеваниями, ассоциированными с Helicobacter pylori. Тер. архив. 2014;86(8):56-61.</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Li G, Li L, Yu C, Chen L. Effect of vitamins C and E supplementation on Helicobacter pylori eradication: a meta-analysis. Br J Nutr. 2011;106(11):1632-1637. doi:10.1017/S0007114511003813</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Demirci H, Uygun İlikhan S, Öztürk K, Üstündağ Y, Kurt Ö, Bilici M, Köktürk F, Uygun A. Influence of vitamin C and E supplementation on the eradication rates of triple and quadruple eradication regimens for Helicobacter pylori infection. Turk J Gastroenterol. 2015;26(6):456-460. doi:10.5152/tjg.2015.0233</mixed-citation></ref></ref-list></back></article>
